| 2026-05-08 | 10-Q | 10.2 | Letter Agreement Regarding Equity Awards, dated as of January 20, 2026, between Ocugen, Inc. and Shankar Musunuri. |
|---|
| 2026-02-09 | 8-K | 10.1 | Employment Agreement by and between Ocugen, Inc. and Rita Johnson-Greene, effective as of February 9, 2026. |
|---|
| 2025-11-05 | 10-Q | 10.2 | Subscription Agreement, by and between Ocugen, Inc. and Carisma Therapeutics, Inc., dated August 29, 2025 |
|---|
| 2025-11-05 | 10-Q | 10.1 | Exclusive License Agreement by and between Ocugen, Inc. and Kwangdong Pharmaceutical Co.. |
|---|
| 2025-08-11 | 8-K | 10.2 | Placement Agency Agreement dated August 8, 2025. |
|---|
| 2025-08-11 | 8-K | 10.1 | Form of Securities Purchase Agreement dated August 8, 2025. |
|---|
| 2025-08-04 | 10-Q | 10.1 | Third Amendment to the Exclusive License Agreement between Washington University and Ocugen, Inc., dated June 2, 2025. |
|---|
| 2025-06-23 | 8-K | 10.4 | Form of Lock-Up Agreement |
|---|
| 2025-06-23 | 8-K | 10.3 | Form of OrthoCellix Support Agreement |
|---|
| 2025-06-23 | 8-K | 10.2 | Form of Carisma Support Agreement |
|---|
| 2025-06-23 | 8-K | 10.1 | Agreement and Plan of Merger, dated as of June 22, 2025, by and among Carisma Therapeutics Inc., Azalea Merger Sub, Inc., OrthoCellix, Inc. and Ocugen, Inc. |
|---|
| 2025-03-05 | 10-K | 10.38 | Executive Employment Agreement, dated as of September 9, 2024, by and between the Registrant and Ramesh Ramachandran |
|---|
| 2025-02-07 | 8-K/A | 10.3 | Supplement to the Loan and Security Agreement, dated as of November 6, 2024, by and among the Company, Ocugen Opco, Inc., the Agent, and the Lenders. |
|---|
| 2025-02-07 | 8-K/A | 10.2 | Loan and Security Agreement, dated as of November 6, 2024, by and among the Company, Ocugen OpCo, Inc., the Agent, and the Lenders. |
|---|
| 2025-02-07 | 8-K/A | 10.1 | Subscription Agreement, dated as of November 6, 2024, by and among the Company and the Lenders. |
|---|
| 2024-05-14 | 10-Q | 10.1 | Executive Employment Agreement, dated as of March 18, 2024, by and between the Registrant and Huma Qamar |
|---|
| 2024-04-16 | 10-K | 10.25 | Second Amendment to the Exclusive License Agreement by and between the Registrant and The Washington University, dated as of November 28, 2023 |
|---|
| 2024-04-16 | 10-K | 10.22 | Third Amendment to the Co-Development and Commercialization Agreement, dated April 11, 2023, by and between the Registrant and CanSino Biologics, Inc. |
|---|
| 2024-01-08 | 8-K | 10.1 | Form of Performance Restricted Stock Unit Award Agreement |
|---|
| 2023-05-05 | 10-Q | 10.2 | Executive Employment Agreement, dated as of January 13, 2023, by and between the Registrant and Quan Vu |
|---|
| 2023-02-28 | 10-K | 10.31 | First Amendment to Amended and Restated Executive Employment Agreement, dated as of August 26, 2022, by and between the Registrant and Arun Upadhyay |
|---|
| 2023-02-28 | 10-K | 10.30 | Amended and Restated Executive Employment Agreement, dated as of December 16, 2021, by and between the Registrant and Arun Upadhyay |
|---|
| 2023-02-28 | 10-K | 10.23 | First Amendment to the Exclusive License Agreement by and between the Registrant and The Washington University, dated as of January 31, 2023 |
|---|
| 2023-02-28 | 10-K | 10.21 | Second Amendment to the Co-Development and Commercialization Agreement, dated November 21, 2022, by and between the Registrant and CanSino Biologics, Inc. |
|---|
| 2023-02-28 | 10-K | 10.10 | Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Inducement Restricted Stock Unit Awards |
|---|
| 2023-02-28 | 10-K | 10.9 | Form of Non-Qualified Stock Option Agreement for Inducement Non-Qualified Stock Option Awards |
|---|
| 2023-02-28 | 10-K | 10.7 | Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under Ocugen, Inc. 2019 Equity Incentive Plan |
|---|
| 2023-02-28 | 10-K | 10.6 | Form of Non-Qualified Stock Option Agreement under Ocugen, Inc. 2019 Equity Incentive Plan |
|---|
| 2023-02-28 | 10-K | 10.5 | Form of Incentive Stock Option Agreement under Ocugen, Inc. 2019 Equity Incentive Plan |
|---|
| 2022-11-08 | 10-Q | 10.1 | Exclusive License Agreement by and between Ocugen, Inc. and The Washington University, dated as of September 23, 2022 |
|---|
| 2022-06-10 | 8-K | 10.1 | At Market Issuance Sales Agreement, dated June 10, 2022, by and among Ocugen, Inc., Cantor Fitzgerald & Co., Mizuho Securities USA LLC, H.C. Wainwright & Co., LLC, Roth Capital Partners, LLC and Chardan Capital Markets, LLC |
|---|
| 2022-05-06 | 10-Q | 10.3 | First Amendment to Amended and Restated Executive Employment Agreement, dated as of April 27, 2022, by and between the Registrant and Shankar Musunuri |
|---|
| 2022-05-06 | 10-Q | 10.2 | Amended and Restated Employment Agreement, dated as of March 18, 2022, by and between the Registrant and Jessica Crespo |
|---|
| 2022-05-06 | 10-Q | 10.1 | Second Amendment to Co-Development, Supply and Commercialization Agreement, dated as of April 15, 2022, by and between the Registrant and Bharat Biotech International Limited |
|---|
| 2021-11-09 | 10-Q | 10.2 | First Amendment to the Co-Development and Commercialization Agreement, dated September 30, 2021, by and between the Registrant and CanSino Biologics, Inc. |
|---|
| 2021-11-09 | 10-Q | 10.1 | Development and Commercial Supply Agreement, dated September 29, 2021, by and between the Registrant and Bharat Biotech International Limited |
|---|
| 2021-08-06 | 10-Q | 10.3 | Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Inducement Restricted Stock Unit Awards |
|---|
| 2021-08-06 | 10-Q | 10.2 | Form of Stock Option Agreement for Inducement Option Awards |
|---|
| 2021-08-06 | 10-Q | 10.1 | First Amendment to Co-Development, Supply and Commercialization Agreement, dated as of May 29, 2021, by and between the Registrant and Bharat Biotech International Limited |
|---|
| 2021-05-07 | 10-Q | 10.2 | Form of Performance-Vested Stock Option Agreement under Ocugen, Inc. 2019 Equity Incentive Plan |
|---|
| 2021-05-07 | 10-Q | 10.1 | Co-Development, Supply and Commercialization Agreement, dated as of January 31, 2021, by and between the Registrant and Bharat Biotech International Limited |
|---|
| 2021-04-27 | 8-K | 10.1 | Form of Securities Purchase Agreement. |
|---|
| 2021-03-19 | 10-K | 10.12 | Lease Agreement, dated October 9, 2020, by and between the Registrant and WPT Land 2 LP |
|---|
| 2021-03-19 | 10-K | 10.7 | Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement |
|---|
| 2021-02-09 | 8-K | 10.1 | Form of Securities Purchase Agreement. |
|---|
| 2020-08-17 | 8-K | 10.1 | At Market Issuance Sales Agreement, dated August 14, 2020, by and among Ocugen, Inc., Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. |
|---|
| 2020-06-12 | 8-K | 10.1 | Controlled Equity OfferingSM Sales Agreement, dated June 12, 2020, by and between Ocugen, Inc. and Cantor Fitzgerald & Co. |
|---|
| 2020-05-08 | 10-Q | 10.6 | Amendment to Executive Employment Agreement, dated as of January 1, 2020, by and between Registrant and Sanjay Subramanian. |
|---|
| 2020-05-08 | 10-Q | 10.5 | Amended and Restated Employment Agreement, dated as of January 1, 2020, by and between the Registrant and Kelly Beck. |
|---|
| 2020-05-08 | 10-Q | 10.4 | Amended and Restated Employment Agreement, dated as of January 1, 2020, by and between the Registrant and Vijay Tammara. |
|---|
| 2020-05-08 | 8-K | 10.1 | Controlled Equity OfferingSM Sales Agreement, dated May 8, 2020, by and between Ocugen, Inc. and Cantor Fitzgerald & Co. |
|---|
| 2020-05-01 | 8-K | 10.1 | Note dated April 30, 2020, between Ocugen, Inc. and Silicon Valley Bank. |
|---|
| 2020-04-22 | 8-K | 10.2 | Form of Promissory Note dated April 22, 2020, issued by Ocugen Inc. |
|---|
| 2020-04-22 | 8-K | 10.1 | Form of Amendment and Exchange Agreement dated as of April 22, 2020, by and between Ocugen, Inc., Ocugen Opco, Inc. and the Investor named therein. |
|---|
| 2020-03-27 | 10-K | 10.30 | Form of Nonstatutory Stock Option Agreement under Ocugen, Inc. 2019 Equity Incentive Plan |
|---|
| 2020-03-27 | 10-K | 10.29 | Form of Incentive Stock Option Agreement under Ocugen, Inc. 2019 Equity Incentive Plan |
|---|
| 2020-01-03 | 8-K | 10.3 | Amended and Restated Employment Agreement, dated January 1, 2020, by and between Ocugen, Inc. and Rasappa Arumugham |
|---|
| 2020-01-03 | 8-K | 10.2 | Amended and Restated Employment Agreement, dated January 1, 2020, by and between Ocugen, Inc. and Daniel Jorgensen |
|---|
| 2020-01-03 | 8-K | 10.1 | Amended and Restated Employment Agreement, dated January 1, 2020, by and between Ocugen, Inc. and Shankar Musunuri |
|---|
| 2019-11-12 | 10-Q | 10.3 | Employment Agreement, dated as of September 10, 2019, by and between the Registrant and Sanjay Subramanian. |
|---|
| 2019-11-12 | 10-Q | 10.2 | Co-Development and Commercialization Agreement, dated as of September 27, 2019, by and among the Registrant and CanSino Biologics Inc. |
|---|
| 2019-10-07 | 8-K | 10.1 | Amendment No. 2 to Asset Purchase Agreement, dated October 4, 2019, by and between the Company and Medavate Corp. |
|---|
| 2019-10-01 | 8-K | 10.1 | Amendment No. 1 to Asset Purchase Agreement, dated September 26, 2019, by and between the Company and Medavate Corp. |
|---|
| 2019-07-03 | 8-K | 10.1 | Form of Amendment to Securities Purchase Agreement, dated as of June 28, 2019, by and among Histogenics Corporation, Ocugen, Inc. and the investor named therein. |
|---|
| 2019-06-14 | 8-K | 10.2 | Form of Lock-Up Agreement. |
|---|
| 2019-06-14 | 8-K | 10.1 | Securities Purchase Agreement, dated as of June 13, 2019, by and among Histogenics Corporation, Ocugen, Inc. and certain investors named therein. |
|---|
| 2019-05-15 | 10-Q | 10.4 | Separation Agreement dated March 19, 2019 between the Registrant and Stephen Kennedy |
|---|
| 2019-05-15 | 10-Q | 10.3 | Separation Agreement dated March 18, 2019 between the Registrant and Adam Gridley |
|---|
| 2019-05-15 | 10-Q | 10.2 | Separation Agreement dated January 23, 2019 between the Registrant and Lynne Kelley, M.D., FACs |
|---|
| 2019-05-15 | 10-Q | 10.1 | Separation Agreement dated January 23, 2019 between the Registrant and Donald Haut, Ph.D. |
|---|
| 2019-05-13 | 8-K | 10.1 | Asset Purchase Agreement dated May 8, 2019 by and between Histogenics Corporation and Medavate Corp. |
|---|
| 2019-02-08 | 8-K | 10.2 | Form of 2018 Warrant Exercise Agreement. |
|---|
| 2019-02-08 | 8-K | 10.1 | Form of 2016 Warrant Amendment and Exercise Agreement. |
|---|
| 2018-12-21 | 8-K | 10.2 | Consulting Agreement, effective December 21, 2018, between the Company and Danforth Advisors, LLC |
|---|
| 2018-12-21 | 8-K | 10.1 | Mutual Termination and Release Agreement dated December 21, 2018, between Histogenics Corporation and Intrexon Corporation. |
|---|
| 2018-10-02 | 8-K | 10.34 | Histogenics Corporation Executive Officer Retention Bonus Plan |
|---|
| 2018-03-15 | 10-K | 10.33 | License and Commercialization Agreement dated as of December 21, 2017 between the Company and MEDINET Co., Ltd. |
|---|
| 2018-03-15 | 8-K | 10.1 | Equity Distribution Agreement, dated as of March 15, 2018, by and between Histogenics Corporation and Canaccord Genuity, Inc. |
|---|
| 2017-10-12 | 8-K | 10.39 | Amended and Restated Employment Agreement by and between Histogenics Corporation and Stephen Kennedy dated October 10, 2017. |
|---|
| 2017-08-10 | 10-Q | 10.33 | Second Amendment to Lease dated April 28, 2017 between the Registrant and CRP/King 830 Winter, L.L.C. |
|---|
| 2017-03-16 | 10-K | 10.32 | Employment Agreement by and between the Registrant and Gloria Matthews, DVM, Ph.D., DACVS, entered into as of July 14, 2015 |
|---|
| 2016-09-29 | 8-K | 10.36 | Form of Support Agreement |
|---|
| 2016-09-29 | 8-K | 10.35 | Registration Rights Agreement dated September 29, 2016 |
|---|
| 2016-09-16 | 8-K | 10.34 | Securities Purchase Agreement dated September 15, 2016 |
|---|
| 2016-08-11 | 10-Q | 10.33 | First Amendment to License Agreement, dated May 9, 2016, between the Registrant and Purpose Co., Ltd., f/k/a Takagi Sangyo Co. Ltd. |
|---|
| 2016-05-04 | 8-K | 10.4 | Histogenics Corporation 2013 Employee Stock Purchase Plan |
|---|
| 2016-05-04 | 8-K | 10.3 | Histogenics Corporation 2013 Equity Incentive Plan |
|---|
| 2016-03-10 | 10-K | 10.32 | Amended and Restated Compensation Program for Non-Employee Directors adopted on June 24, 2015 |
|---|
| 2015-07-30 | 8-K | 10.39 | Amended and Restated Employment Agreement by and between Histogenics Corporation and Stephen Kennedy dated July 29, 2015. |
|---|
| 2015-06-22 | 8-K | 10.38 | Employment Agreement, by and between Histogenics Corporation and Jonathan Lieber, dated as of June 17, 2015. |
|---|
| 2015-05-14 | 10-Q | 10.37 | Consulting Agreement, dated March 12, 2015, between the Registrant and Danforth Consulting LLC |
|---|
| 2015-02-27 | 8-K | 10.36 | Separation Agreement, effective February 26, 2015 between the Company and Nancy Lynch, M.D. |
|---|